罗莫佐单抗或阿仑膦酸钠预防东亚患者骨折:ARCH III期随机研究亚组分析
ARCH研究东亚亚组纳入275例来自香港、韩国和台湾的绝经后骨质疏松性骨折女性,随机接受罗莫佐单抗210mg/月或阿仑膦酸钠70mg/周治疗12个月,之后均开放标签阿仑膦酸钠。罗莫佐单抗序贯阿仑膦酸钠较阿仑膦酸钠单药降低24个月新发椎体骨折风险60%(P=0.11)和临床骨折风险44%(P=0.15),并显著提高24个月腰椎、全髋和股骨颈骨密度。
要点
- 东亚亚组中罗莫佐单抗序贯阿仑膦酸钠较阿仑膦酸钠单药降低新发椎体骨折风险60%(P=0.11)。
- 临床骨折风险降低44%(P=0.15),但事后分析未设效能检测骨折率差异。
- 24个月骨密度较基线进一步增加:腰椎9.0%、全髋3.3%、股骨颈3.0%。
核心结论
- 与全球分析一致,东亚患者中罗莫佐单抗序贯阿仑膦酸钠较阿仑膦酸钠单药与新发椎体、临床、非椎体和髋部骨折发生率降低相关。
研究设计与样本
- ARCH III期随机研究的东亚患者事后亚组分析,纳入275例来自香港、韩国和台湾的绝经后骨质疏松性骨折女性。
- 患者随机1:1接受罗莫佐单抗210mg/月或阿仑膦酸钠70mg/周治疗12个月,之后均开放标签阿仑膦酸钠。
- 该事后分析未设效能检测骨折率差异。
主要发现
- 罗莫佐单抗序贯阿仑膦酸钠较阿仑膦酸钠单药降低24个月新发椎体骨折风险60%(P=0.11)。
- 主要分析时临床骨折风险降低44%(P=0.15)。
- 24个月时腰椎、全髋和股骨颈骨密度较基线进一步增加9.0%、3.3%和3.0%。
- 不良事件率组间相似,12个月时positively adjudicated严重心血管不良事件发生率罗莫佐单抗组1.6%、阿仑膦酸钠组1.4%。
临床怎么用
- 东亚高风险绝经后骨质疏松性骨折女性可考虑罗莫佐单抗序贯阿仑膦酸钠以降低骨折风险并提高骨密度。
局限性
- 该分析为事后亚组分析,未设效能检测骨折率差异。
- 样本量较小(275例),骨折风险降低的P值未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Romosozumab, a sclerostin antibody, exerts dual effect to increase bone formation and decrease bone resorption. Among high-risk postmenopausal East Asian women, romosozumab followed by alendronate was associated with lower incidences of fractures vs alendronate alone. Romosozumab demonstrates potential to address an unmet need in osteoporosis management in Asia. INTRODUCTION: Romosozumab, a sclerostin antibody, exerts dual effect to increase bone formation and decrease bone resorption. The global ARCH study demonstrated superiority of romosozumab followed by alendronate in reducing fracture risk in high-risk postmenopausal osteoporotic women vs alendronate alone. We report outcomes among ARCH East Asian patients. METHODS: In ARCH, 4093 postmenopausal osteoporotic women with fragility fracture were randomized 1:1 to monthly romosozumab 210 mg or weekly alendronate 70 mg for 12 months, both followed by open-label alendronate. Primary endpoints were incidence of new vertebral fracture (VF) at 24 months and clinical fracture at primary analysis (confirmed fractures in ≥ 330 patients and all patients had opportunity to attend month 24 visit). This post hoc analysis was not powered to detect fracture-rate differences. RESULTS: This analysis included 275 patients from Hong Kong, Korea, and Taiwan. Romosozumab followed by alendronate reduced risk of new VFs at 24 months by 60% (P = 0.11) and clinical fractures at primary analysis by 44% (P = 0.15) vs alendronate alone. Romosozumab followed by alendronate significantly increased mean bone mineral density at 24 months from baseline by a further 9.0%, 3.3%, and 3.0% at the lumbar spine, total hip, and femoral neck vs alendronate alone. Adverse event (AE) rates, including positively adjudicated serious cardiovascular AEs (1.6% vs 1.4% at 12 months for romosozumab vs alendronate), were similar across treatment groups. CONCLUSIONS: Consistent with the global analysis, romosozumab followed by alendronate was associated with lower incidences of new vertebral, clinical, non-vertebral, and hip fractures vs alendronate alone among East Asian patients.
引用
- Lau EMC, Dinavahi R, Woo YC, et al. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study. Osteoporos Int. 2020. PMID: 32047951. doi:10.1007/s00198-020-05324-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。